Molecular Diagnostics a Natural Fit for Breast Cancer
The growing global incidence of breast cancer has led to an increased demand for molecular diagnostics tests that aid in diagnosing breast cancer.
cancer
Oncology, Pain Management
Infinity Pharmaceuticals is a biopharmaceutical company that has developed a targeted drug development platform to actualize small molecule inhibitors against specific bioactive proteins that play critical roles in biological…
Oncology Drugs Experience Sales Slowdown In U.S.
Cancer drug sales are slowing down in the U.S., Reuters reported Monday.
GE Healthcare to Acquire Diagnostics Company Clarient
General Electric announced Friday that its healthcare unit will acquire molecular diagnostics company Clarient in a deal worth approximately $580 million.
Genomics Researchers Have a Bone to Pick with Multiple Myeloma
Signal Genetics, a predictive genetic testing company focused on oncology, recently announced that it would work with pharmaceutical company Array BioPharma to advance both companies’ goals of finding biomarkers for myeloma patients.
China Analyst Identifies 10 Pharma Stocks with Highest Growth Potential
China Analyst, a financial information website focused on U.S.-listed Chinese stocks, recently released its list of the top 10 pharmaceutical stocks with the highest upside.
The Ambitious Pipeline of EpiCept Corporation
EpiCept’s lead product, Ceplene, is approved for marketing in the EU for the maintenance of first remission in patients with acute myeloid leukemia.
Ascalon Leverages Experienced Management Team, Strategic Partnerships for Cancer Drug Development
Ascalon International is a privately held oncology-focused drug development company based in Scottsdale, Arizona.
Adventrx Pharmaceuticals Seeks to Improve Current Cancer Drugs
The San Diego-based company seeks to improve upon existing cancer therapeutics with its reformulations of the chemotherapy drugs Navelbine and Taxotere.
OneMedForum to Highlight the Newest, Most Promising Med Tech Innovations
OneMedPlace announced that it will showcase to investors and entrepreneurs the newest and most promising new medical technologies in the region.